Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance

BMJ. 2008 May 31;336(7655):1246-8. doi: 10.1136/bmj.39554.624086.AD.

Authors

Angela Cooper¹, Norma O'Flynn; Guideline Development Group

Collaborators

Guideline Development Group:
John Robson, Peter Brindle, Paramjit Gill, Renu Gujral, Maureen Hogg, Tom Marshall, Rubin Minhas, Lesley Pavitt, John Reckless, Alaster Rutherford, Margaret Thorogood, David Wood, Phill Bath, Norma O'Flynn, Angela Cooper, Neill Calvert, Leo Nherera, Tim Stokes, Nancy Turnbull, Chris Rule, Rifna Mannan, Nicola Browne

Affiliation

¹ National Collaborating Centre for Primary Care, Royal College of General Practitioners, London SW7 1PU.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adult
Cardiovascular Diseases / prevention & control*
Cholesterol / blood
Counseling
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypolipidemic Agents / therapeutic use*
Life Style
Male
Patient Education as Topic / methods
Practice Guidelines as Topic
Risk Assessment / methods

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Cholesterol